OticPharma to Present at the 28th Annual ROTH Conference

IRVINE, Calif. and REHOVOT, Israel, March 10, 2016 /PRNewswire/ — OticPharma, Ltd., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced that Gregory J. Flesher, chief executive officer, will provide an overview of the company at the upcoming 28th Annual ROTH Conference to be held at the Ritz-Carlton in Laguna Niguel, California.

  • Date:  Tuesday, March 15, 2016
  • Time:  4:20 p.m. Pacific Time
  • Room:  Pacific Promenade 1

About OticPharma

OticPharma is a clinical-stage pharmaceutical company focusing on the acquisition and development of ear, nose, and throat (ENT) products that restore health and address unmet needs in children and adults.  The company’s proprietary foam technology (OP-01) is currently being developed for acute otitis externa (“swimmers ear”) and is also being explored for the treatment of nasal and sinus conditions.  The company’s proprietary surfactant technology (OP-02) is currently being developed as a potential first-in-class, antibiotic-free treatment option for acute, recurrent, and chronic otitis media.

Investor and Media Contact

Gita Ogawa
The Trout Group
Gogawa@troutgroup.com
Tel: +1 (646) 378-2949

Company Contact

Gregory J. Flesher
OticPharma, Ltd.
gflesher@oticpharma.com
Tel: +1 (949) 238-8090